STUART A. RANDLE - 04 Jan 2023 Form 4 Insider Report for Comera Life Sciences Holdings, Inc.

Role
Director
Signature
/s/ Ryan M. Rourke Reed, Attorney-in-Fact
Issuer symbol
CMRA on OTC
Transactions as of
04 Jan 2023
Net transactions value
+$49,999
Form type
4
Filing time
06 Jan 2023, 15:14:44 UTC
Previous filing
14 Feb 2023
Next filing
16 Feb 2023
This filing has been restated, see here for the amended filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CMRA Common Stock Award $41,553 +33,783 +389% $1.23 42,469 04 Jan 2023 Direct F1
holding CMRA Common Stock 31,647 04 Jan 2023 The Stuart A. Randle Trust of 1998 F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMRA Warrants (right to buy) Award $8,446 +33,783 $0.2500 33,783 04 Jan 2023 Common Stock 67,566 $1.23 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person entered into a Securities Purchase Agreement with the Issuer on January 2, 2023, pursuant to which, on January 4, 2023, the reporting person acquired an aggregate of 33,783 units (the "Units") for a purchase price of $1.48 per Unit. Each Unit consists of one share of common stock, par value $0.0001 per share (the "Common Stock"), and one warrant (the "Warrants") to purchase two shares of Common Stock (the "Warrant Shares") at an exercise price of $1.23 per share. Each Warrant is immediately exercisable and expires five years from the date of issuance. The purchase price for each Unit includes $0.125 for each Warrant Share, or $0.25 per Warrant, in accordance with Nasdaq rules.
F2 These shares are owned directly by The Stuart A. Randle Trust of 1998 (the "Trust"). Mr. Stuart Randle is the trustee of the Trust, and may be deemed to be a beneficial owner of these shares.
F3 The exercisability of the Warrants is subject to a 4.99% beneficial ownership limitation.